[go: up one dir, main page]

MX2019009190A - Uso de gaboxadol en el tratamiento de tinnitus. - Google Patents

Uso de gaboxadol en el tratamiento de tinnitus.

Info

Publication number
MX2019009190A
MX2019009190A MX2019009190A MX2019009190A MX2019009190A MX 2019009190 A MX2019009190 A MX 2019009190A MX 2019009190 A MX2019009190 A MX 2019009190A MX 2019009190 A MX2019009190 A MX 2019009190A MX 2019009190 A MX2019009190 A MX 2019009190A
Authority
MX
Mexico
Prior art keywords
gaboxadol
tinnitus
treatment
meniere
symptoms
Prior art date
Application number
MX2019009190A
Other languages
English (en)
Other versions
MX393900B (es
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2019009190A publication Critical patent/MX2019009190A/es
Publication of MX393900B publication Critical patent/MX393900B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos para el tratamiento de tinnitus con gaboxadol o con una sal farmacéuticamente aceptable del mismo. También se proporcionan composiciones terapéuticas que se pueden utilizar con el fin de mejorar uno o más síntomas del tinnitus. Se proporcionan métodos para el tratamiento de la pérdida aguda de la audición neurosensorial o de la enfermedad de Meniere con gaboxadol o con una sal farmacéuticamente aceptable del mismo. También se proporcionan composiciones terapéuticas que se pueden utilizar con el fin de mejorar uno o más síntomas de la pérdida aguda de la audición neurosensorial o de la enfermedad de Meniere.
MX2019009190A 2017-02-03 2018-02-02 Uso de gaboxadol en el tratamiento de tinnitus. MX393900B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762454280P 2017-02-03 2017-02-03
US201762530528P 2017-07-10 2017-07-10
US201762536669P 2017-07-25 2017-07-25
PCT/US2018/016602 WO2018144827A1 (en) 2017-02-03 2018-02-02 Use of gaboxadol in the treatment of tinnitus

Publications (2)

Publication Number Publication Date
MX2019009190A true MX2019009190A (es) 2019-09-26
MX393900B MX393900B (es) 2025-03-24

Family

ID=63038963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009190A MX393900B (es) 2017-02-03 2018-02-02 Uso de gaboxadol en el tratamiento de tinnitus.

Country Status (17)

Country Link
US (3) US10071083B2 (es)
EP (1) EP3576738B1 (es)
JP (3) JP2020505432A (es)
KR (1) KR20190112046A (es)
CN (1) CN110402140A (es)
AU (1) AU2018215363A1 (es)
BR (1) BR112019015832A2 (es)
CA (1) CA3051586A1 (es)
DK (1) DK3576738T3 (es)
ES (1) ES2930899T3 (es)
HU (1) HUE060609T2 (es)
IL (1) IL268210A (es)
MX (1) MX393900B (es)
PE (1) PE20191407A1 (es)
PL (1) PL3576738T3 (es)
PT (1) PT3576738T (es)
WO (1) WO2018144827A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014393A1 (en) 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CN112930182A (zh) 2018-09-20 2021-06-08 奥维德医疗公司 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
WO2020131856A1 (en) * 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2561883A1 (en) 2004-04-02 2005-10-13 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
DE102005004343A1 (de) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
RS55585B1 (sr) 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
DE102007063210A1 (de) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
WO2013056159A1 (en) 2011-10-13 2013-04-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
CA2951497C (en) 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170014393A1 (en) * 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US20180235942A1 (en) 2015-08-11 2018-08-23 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
KR20210110585A (ko) * 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
US10188635B2 (en) 2019-01-29
IL268210A (en) 2019-09-26
PE20191407A1 (es) 2019-10-04
HUE060609T2 (hu) 2023-04-28
US20190111033A1 (en) 2019-04-18
US20180344709A1 (en) 2018-12-06
PL3576738T3 (pl) 2023-02-06
US20180221355A1 (en) 2018-08-09
MX393900B (es) 2025-03-24
JP2020505432A (ja) 2020-02-20
ES2930899T3 (es) 2022-12-22
EP3576738A4 (en) 2021-02-17
KR20190112046A (ko) 2019-10-02
JP2024178317A (ja) 2024-12-24
CA3051586A1 (en) 2018-08-09
DK3576738T3 (da) 2022-11-28
US10071083B2 (en) 2018-09-11
AU2018215363A1 (en) 2019-08-15
JP2023011630A (ja) 2023-01-24
CN110402140A (zh) 2019-11-01
BR112019015832A2 (pt) 2020-03-31
WO2018144827A1 (en) 2018-08-09
PT3576738T (pt) 2022-11-30
EP3576738B1 (en) 2022-10-12
EP3576738A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2024010140A (es) Nuevos metodos.
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX2021002322A (es) Nuevos metodos.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
MX2019014024A (es) Tratamiento de los trastornos depresivos.
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
MX2018003023A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2018001720A (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX394475B (es) Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes.
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2016010699A (es) Composiciones y metodos para tratar neutropenia.
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.